HCW Biologics regains compliance with Nasdaq's minimum bid price HCW Biologics has regained compliance with Nasdaq's minimum bid price requirement. The company will remain under a mandatory Nasdaq monitoring period through June 17, 2027. To support long-term comp
HCW Biologics regains compliance with Nasdaq’s minimum bid price
HCW Biologics has regained compliance with Nasdaq’s minimum bid price requirement.
The company will remain under a mandatory Nasdaq monitoring period through June 17, 2027.
To support long-term compliance, HCW Biologics will implement a 1-for-6 reverse stock split effective June 30, 2026.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
